title: [Cost analysis of Shenqi Fuzheng injection on reducing adverse effects during chemotherapy].
abstract: OBJECTIVE
  The goals of this work was to analyse the cost of Shenqi Fuzheng injection-an extraction of a Chinese traditional herbs on reducing adverse effects in lung cancer patients during chemotherapy.
  
  
  METHODS
  In a randomized cross-over trial, each patient completed two identical cisplatin-based chemotherapy cycles, one with Shenqi Fuzheng injection, another without Shenqi Fuzheng injection. Adverse effects and change scores of quality of life (QOL) during chemotherapy were compared in tow cycles. The direct cost dealing with adverse effect and cost-effectiveness analysis were taken.
  
  
  RESULTS
  One hundred and thirty were enrolled with 123 of whom were evaluable. The patient characteristics were well balanced between the two groups. The chemotherapy cycles with Shenqi Fuzheng injection spent 220.5 more Chinese yuan, but the adverse effect of leukopenia, thrombocytopenia and vomiting were slight different and the change of score of several QOL domains showed significant better as compared to those in another cycle.
  
  
  CONCLUSIONS
  Shenqi Fuzheng injection could reduce the severity of toxicity related to chemotherapy and improve the QOL of patients and had some benefits in terms of cost-effectiveness.
authors.affiliation: Department of Pulmonary Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
authors.forename: Chang-qing
authors.initials: CQ
authors.lastname: Bai
authors.forename: Dian-tao
authors.initials: DT
authors.lastname: Ni
authors.forename: Ning-xiu
authors.initials: NX
authors.lastname: Li
authors.forename: Guan-jian
authors.initials: GJ
authors.lastname: Liu
authors.forename: Bi-rong
authors.initials: BR
authors.lastname: Dong
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D018592:Cross-Over Studies; D004365:Drugs, Chinese Herbal / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal